Replacing PCV7 with universal childhood PCV13 immunization resulted in declining incidence of invasive pneumococcal disease and all-cause pneumonia in US adults; however, the decline was attenuated with increasing age and in those with comorbidities. This according to a retrospective study that evaluated the impact of replacing PCV7 with PCV13 on disease burden in adults and identified age/risk-specific subgroups with highest remaining disease burden. Study population included adults aged ≥18 years, stratified by age (18-49, 50-64, 65-74, and ≥75) and risk profile (healthy, at-risk, high-risk). Rate ratios comparing invasive pneumococcal disease (IPD), all-cause hospitalized pneumonia (ACHP), and pneumococcal pneumonia requiring hospitalization among at-risk and high-risk adults vs healthy counterparts, were estimated for 2007-2010 (pre-PCV13), 2011-2012 (peri-PCV13), and 2013-2015 (post-PCV13). Researchers found:

• IPD and ACHP rates increased with age and comorbidity across study periods.
• IPD rates declined 5-48% and ACHP rates declined 4-19% across age and risk groups from pre- to post-PCV13 period.
• The decline in IPD and ACHP was attenuated among older adults and those with comorbidities.